102 citations,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Restoring hair bulb immune privilege is crucial for managing alopecia areata.
101 citations,
July 2020 in “Dermatologic therapy” COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
95 citations,
November 2018 in “Australasian journal of dermatology” Alopecia areata treatment varies, with no optimal method established yet.
53 citations,
April 2018 in “Journal of The American Academy of Dermatology” Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
52 citations,
September 2018 in “International Journal of Molecular Sciences” Ginseng and its compounds may help hair growth and prevent hair loss, but more human trials are needed to confirm this.
42 citations,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
28 citations,
December 2017 in “Lasers in Medical Science” Monochromatic light devices, especially the 308-nm excimer laser, are promising for treating alopecia areata but more research is needed.
22 citations,
August 2017 in “Stem cells and cloning” Stem cell technologies and regenerative medicine, including platelet-rich plasma, show promise for hair restoration in treating hair loss, but more research is needed.
17 citations,
March 2018 in “Pediatric dermatology” Hydroxychloroquine may help treat alopecia areata in children.
11 citations,
November 2021 in “BMJ Open” People with alopecia areata have higher rates of mental health issues, autoimmune diseases, and infections.
7 citations,
January 2021 in “Dermatology and therapy” Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
6 citations,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Stephen Rothman made important discoveries in dermatology, including the use of PABA in sunscreens, but never profited from his work.
3 citations,
September 2023 in “Frontiers in immunology” Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.
3 citations,
August 2021 in “Cutis” Some alternative medicine treatments might work for skin conditions, but their effectiveness and safety differ a lot.
1 citations,
April 2020 in “Plastic and Aesthetic Nursing” PRP therapy might help increase hair growth for nonscarring alopecia, but more research is needed to confirm its effectiveness.
May 2024 in “Journal of Education, Health and Sport” Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.
April 2024 in “Dermatology and therapy” There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.
April 2024 in “Dermatology and therapy” In Denmark from 1995 to 2016, hospital-treated alopecia areata cases increased, mostly affecting women and those over 50.
March 2024 in “Clinical and experimental dermatology” Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.
February 2024 in “International neuropsychiatric disease journal” Alopecia areata severely impacts quality of life, mental health, and work productivity.
Baricitinib is a new, effective treatment for advanced alopecia areata but is costly and has risks.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
June 2020 in “Journal of Dermatological Treatment” Use telemedicine and strict hygiene for safe hair and scalp treatments during COVID-19.
July 2018 in “Elsevier eBooks” The most common cause of hair loss in children is tinea capitis, followed by alopecia areata and telogen effluvium.
6 citations,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
1 citations,
June 2023 in “Dermatology and therapy” People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
4 citations,
September 2022 in “Dermatologic Therapy” Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.